{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:54:03Z","timestamp":1792857243854,"version":"4.5.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32GM135142"],"award-info":[{"award-number":["T32GM135142"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005909","name":"University of California Institute for Mexico and the United States","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005909","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["CMMI-2027668"],"award-info":[{"award-number":["CMMI-2027668"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["CMMI-2027668"],"award-info":[{"award-number":["CMMI-2027668"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Nanotechnol."],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1038\/s41565-020-0737-y","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T10:04:02Z","timestamp":1594807442000},"page":"646-655","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":577,"title":["COVID-19 vaccine development and a potential nanomaterial path forward"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2516-5712","authenticated-orcid":false,"given":"Matthew D.","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourabh","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6578-8076","authenticated-orcid":false,"given":"Young Hun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Beiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Khim","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0773-0677","authenticated-orcid":false,"given":"Oscar A.","family":"Ortega-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0383-7626","authenticated-orcid":false,"given":"David M.","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6698-9996","authenticated-orcid":false,"given":"Angela","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Sack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan K.","family":"Pokorski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0130-0481","authenticated-orcid":false,"given":"Nicole F.","family":"Steinmetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"key":"737_CR1","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","volume":"395","author":"C Wang","year":"2020","unstructured":"Wang, C., Horby, P. W., Hayden, F. G. & Gao, G. F. A novel coronavirus outbreak of global health concern. Lancet 395, 470\u2013473 (2020).","journal-title":"Lancet"},{"key":"737_CR2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","volume":"5","author":"AE Gorbalenya","year":"2020","unstructured":"Gorbalenya, A. E. et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5, 536\u2013544 (2020).","journal-title":"Nat. Microbiol."},{"key":"737_CR3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.24171\/j.phrp.2020.11.1.02","volume":"11","author":"JM Kim","year":"2020","unstructured":"Kim, J. M. et al. Identification of coronavirus isolated from a patient in Korea with COVID-19. Osong Public Health Res. Perspect. 11, 3\u20137 (2020).","journal-title":"Osong Public Health Res. Perspect."},{"key":"737_CR4","unstructured":"Institute of Medicine (US) Forum on Microbial Threats. The Threat of Pandemic Influenza: Are We Ready? Workshop Summary (National Academies Press, 2005)."},{"key":"737_CR5","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1126\/science.abb5793","volume":"368","author":"SM Kissler","year":"2020","unstructured":"Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H. & Lipsitch, M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science 368, 860\u2013868 (2020).","journal-title":"Science"},{"key":"737_CR6","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/bmj.m1375","volume":"369","author":"M Day","year":"2020","unstructured":"Day, M. Covid-19: four fifths of cases are asymptomatic, China figures indicate. BMJ 369, 1375 (2020).","journal-title":"BMJ"},{"key":"737_CR7","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1056\/NEJMc2009316","volume":"382","author":"D Sutton","year":"2020","unstructured":"Sutton, D., Fuchs, K., D\u2019Alton, M. & Goffman, D. Universal screening for SARS-CoV-2 in women admitted for delivery. N. Engl. J. Med. 382, 2163\u20132164 (2020).","journal-title":"N. Engl. J. Med."},{"key":"737_CR8","doi-asserted-by":"crossref","first-page":"2000180","DOI":"10.2807\/1560-7917.ES.2020.25.10.2000180","volume":"25","author":"K Mizumoto","year":"2020","unstructured":"Mizumoto, K., Kagaya, K., Zarebski, A. & Chowell, G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Eur. Surveill. 25, 2000180 (2020).","journal-title":"Eur. Surveill."},{"key":"737_CR9","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1128\/CMR.00023-07","volume":"20","author":"VCC Cheng","year":"2007","unstructured":"Cheng, V. C. C., Lau, S. K. P., Woo, P. C. Y. & Yuen, K. Y. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin. Microbiol. Rev. 20, 660\u2013694 (2007).","journal-title":"Clin. Microbiol. Rev."},{"key":"737_CR10","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"737_CR11","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","volume":"26","author":"KG Andersen","year":"2020","unstructured":"Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C. & Garry, R. F. The proximal origin of SARS-CoV-2. Nat. Med. 26, 450\u2013452 (2020).","journal-title":"Nat. Med."},{"key":"737_CR12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jmv.25688","volume":"92","author":"D Benvenuto","year":"2020","unstructured":"Benvenuto, D. et al. The 2019-new coronavirus epidemic: Evidence for virus evolution. J. Med. Virol. 92, 455\u2013459 (2020).","journal-title":"J. Med. Virol."},{"key":"737_CR13","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1126\/science.abb7269","volume":"368","author":"M Yuan","year":"2020","unstructured":"Yuan, M. et al. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science 368, 630\u2013633 (2020).","journal-title":"Science"},{"key":"737_CR14","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","volume":"367","author":"R Yan","year":"2020","unstructured":"Yan, R. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444\u20131448 (2020).","journal-title":"Science"},{"key":"737_CR15","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41423-020-0377-z","volume":"17","author":"G Lucchese","year":"2020","unstructured":"Lucchese, G. Epitopes for a 2019-nCoV vaccine. Cell. Mol. Immunol. 17, 539\u2013540 (2020).","journal-title":"Cell. Mol. Immunol."},{"key":"737_CR16","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.chom.2020.03.002","volume":"27","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. Cell Host Microbe 27, 671\u2013680e2 (2020).","journal-title":"Cell Host Microbe"},{"key":"737_CR17","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/jmv.25698","volume":"92","author":"V Baruah","year":"2020","unstructured":"Baruah, V. & Bose, S. Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV. J. Med. Virol. 92, 495\u2013500 (2020).","journal-title":"J. Med. Virol."},{"key":"737_CR18","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3390\/v12030254","volume":"12","author":"SF Ahmed","year":"2020","unstructured":"Ahmed, S. F., Quadeer, A. A. & McKay, M. R. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 12, 254 (2020).","journal-title":"Viruses"},{"key":"737_CR19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281\u2013292 (2020).","journal-title":"Cell"},{"key":"737_CR20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280 (2020).","journal-title":"Cell"},{"key":"737_CR21","volume":"11","author":"C Lei","year":"2020","unstructured":"Lei, C. et al. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat. Commun. 11, 2070 (2020).","journal-title":"Nat. Commun."},{"key":"737_CR22","volume":"11","author":"C Wang","year":"2020","unstructured":"Wang, C. et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat. Commun. 11, 2251 (2020).","journal-title":"Nat. Commun."},{"key":"737_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215\u2013220 (2020).","journal-title":"Nature"},{"key":"737_CR24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/bs.aivir.2016.08.003","volume":"96","author":"L Enjuanes","year":"2016","unstructured":"Enjuanes, L. et al. Molecular basis of coronavirus virulence and vaccine development. Adv. Virus Res. 96, 245\u2013286 (2016).","journal-title":"Adv. Virus Res."},{"key":"737_CR25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/v11010059","volume":"11","author":"Z Song","year":"2019","unstructured":"Song, Z. et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses 11, 59 (2019).","journal-title":"Viruses"},{"key":"737_CR26","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12985-019-1182-0","volume":"16","author":"D Schoeman","year":"2019","unstructured":"Schoeman, D. & Fielding, B. C. Coronavirus envelope protein: current knowledge. Virol. J. 16, 69 (2019).","journal-title":"Virol. J."},{"key":"737_CR27","doi-asserted-by":"publisher","unstructured":"Xia, S. et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell. Mol. Immunol. https:\/\/doi.org\/10.1038\/s41423-020-0374-2 (2020).","DOI":"10.1038\/s41423-020-0374-2"},{"key":"737_CR28","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3389\/fmicb.2020.00298","volume":"11","author":"N Wang","year":"2020","unstructured":"Wang, N., Shang, J., Jiang, S. & Du, L. Subunit vaccines against emerging pathogenic human coronaviruses. Front. Microbiol. 11, 298 (2020).","journal-title":"Front. Microbiol."},{"key":"737_CR29","doi-asserted-by":"crossref","unstructured":"Wu, F. et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. Preprint at https:\/\/www.medrxiv.org\/content\/10.1101\/2020.03.30.20047365v2 (2020).","DOI":"10.2139\/ssrn.3566211"},{"key":"737_CR30","doi-asserted-by":"publisher","unstructured":"Watanabe, Y., Allen, J. D., Wrapp, D., McLellan, J. S. & Crispin, M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science https:\/\/doi.org\/10.1126\/science.abb9983 (2020).","DOI":"10.1126\/science.abb9983"},{"key":"737_CR31","doi-asserted-by":"crossref","unstructured":"Banerjee, A., Santra, D. & Maiti, S. Energetics based epitope screening in SARS CoV-2 (COVID 19) spike glycoprotein by Immuno-informatic analysis aiming to a suitable vaccine development. Preprint at https:\/\/www.biorxiv.org\/content\/10.1101\/2020.04.02.021725v1 (2020).","DOI":"10.1101\/2020.04.02.021725"},{"key":"737_CR32","doi-asserted-by":"crossref","unstructured":"Zhou, D., Qi, R., Zhang, W., Tian, X. & Peng, C. Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: implications on vaccination and antibody therapeutics. Preprint at https:\/\/www.preprints.org\/manuscript\/202002.0381\/v2 (2020).","DOI":"10.20944\/preprints202002.0381.v2"},{"key":"737_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ve\/vev001","volume":"1","author":"JJ Bull","year":"2015","unstructured":"Bull, J. J. Evolutionary reversion of live viral vaccines: Can genetic engineering subdue it? Virus Evol. 1, 1 (2015).","journal-title":"Virus Evol."},{"key":"737_CR34","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1126\/science.aah5869","volume":"354","author":"L Si","year":"2016","unstructured":"Si, L. et al. Generation of influenza A viruses as live but replication-incompetent virus vaccines. Science 354, 1170\u20131173 (2016).","journal-title":"Science"},{"key":"737_CR35","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-020-2294-9","volume":"582","author":"TTN Thao","year":"2020","unstructured":"Thao, T. T. N. et al. Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform. Nature 582, 561\u2013565 (2020).","journal-title":"Nature"},{"key":"737_CR36","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.chom.2020.04.004","volume":"27","author":"X Xie","year":"2020","unstructured":"Xie, X. et al. An infectious cDNA clone of SARS-CoV-2. Cell Host Microbe 27, 841\u2013848e3 (2020).","journal-title":"Cell Host Microbe"},{"key":"737_CR37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.smim.2018.10.010","volume":"40","author":"A Ciabattini","year":"2018","unstructured":"Ciabattini, A. et al. Vaccination in the elderly: The challenge of immune changes with aging. Semin. Immunol. 40, 83\u201394 (2018).","journal-title":"Semin. Immunol."},{"key":"737_CR38","doi-asserted-by":"crossref","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","volume":"7","author":"MDJ Dicks","year":"2012","unstructured":"Dicks, M. D. J. et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PloS One 7, e40385 (2012).","journal-title":"PloS One"},{"key":"737_CR39","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.4161\/hv.29594","volume":"10","author":"H Fausther-Bovendo","year":"2014","unstructured":"Fausther-Bovendo, H. & Kobinger, G. P. Pre-existing immunity against Ad vectors. Hum. Vaccines Immunother. 10, 2875\u20132884 (2014).","journal-title":"Hum. Vaccines Immunother."},{"key":"737_CR40","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","volume":"390","author":"M Alberer","year":"2017","unstructured":"Alberer, M. et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet 390, 1511\u20131520 (2017).","journal-title":"Lancet"},{"key":"737_CR41","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines \u2014 a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"737_CR42","volume":"11","author":"TRF Smith","year":"2020","unstructured":"Smith, T. R. F. et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat. Commun. 11, 2601 (2020).","journal-title":"Nat. Commun."},{"key":"737_CR43","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/14760584.2017.1355245","volume":"16","author":"C Iavarone","year":"2017","unstructured":"Iavarone, C., O\u2019hagan, D. T., Yu, D., Delahaye, N. F. & Ulmer, J. B. Mechanism of action of mRNA-based vaccines. Expert Rev. Vaccines 16, 871\u2013881 (2017).","journal-title":"Expert Rev. Vaccines"},{"key":"737_CR44","unstructured":"BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates. BIONTECH https:\/\/investors.biontech.de\/news-releases\/news-release-details\/biontech-and-pfizer-announce-regulatory-approval-german (2020)."},{"key":"737_CR45","doi-asserted-by":"crossref","unstructured":"Zeng, C. et al. Leveraging mRNAs sequences to express SARS-CoV-2 antigens in vivo. Preprint at https:\/\/www.biorxiv.org\/content\/10.1101\/2020.04.01.019877v1 (2020).","DOI":"10.1101\/2020.04.01.019877"},{"key":"737_CR46","unstructured":"Arcturus Therapeutics and Duke-NUS Medical School partner to develop a coronavirus (COVID-19) vaccine using STARR\u2122 Technology. ARCTURUS therapeutics https:\/\/ir.arcturusrx.com\/news-releases\/news-release-details\/arcturus-therapeutics-and-duke-nus-medical-school-partner (2020)."},{"key":"737_CR47","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/pharmaceutics12010030","volume":"12","author":"M Lim","year":"2020","unstructured":"Lim, M. et al. Engineered nanodelivery systems to improve DNA vaccine technologies. Pharmaceutics 12, 30 (2020).","journal-title":"Pharmaceutics"},{"key":"737_CR48","doi-asserted-by":"crossref","first-page":"7524","DOI":"10.1002\/anie.201102834","volume":"50","author":"Y Takashima","year":"2011","unstructured":"Takashima, Y., Osaki, M., Ishimaru, Y., Yamaguchi, H. & Harada, A. Artificial molecular clamp: A novel device for synthetic polymerases. Angew. Chem. Int. Ed. 50, 7524\u20137528 (2011).","journal-title":"Angew. Chem. Int. Ed."},{"key":"737_CR49","volume":"7","author":"H Liu","year":"2017","unstructured":"Liu, H. et al. Improvement of pharmacokinetic profile of TRAIL via trimer-tag enhances its antitumor activity in vivo. Sci. Rep. 7, 8953 (2017).","journal-title":"Sci. Rep."},{"key":"737_CR50","doi-asserted-by":"crossref","unstructured":"Hotez, P. J. & Bottazzi, M. E. Developing a low-cost and accessible COVID-19 vaccine for global health. Preprint at https:\/\/www.preprints.org\/manuscript\/202003.0464\/v1 (2020).","DOI":"10.1371\/journal.pntd.0008548"},{"key":"737_CR51","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","volume":"162","author":"M Kanekiyo","year":"2015","unstructured":"Kanekiyo, M. et al. Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site. Cell 162, 1090\u20131100 (2015).","journal-title":"Cell"},{"key":"737_CR52","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41590-018-0305-x","volume":"20","author":"M Kanekiyo","year":"2019","unstructured":"Kanekiyo, M. et al. Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Nat. Immunol. 20, 362\u2013372 (2019).","journal-title":"Nat. Immunol."},{"key":"737_CR53","doi-asserted-by":"crossref","first-page":"18211","DOI":"10.1021\/acsami.9b21776","volume":"12","author":"J Sharma","year":"2020","unstructured":"Sharma, J. et al. A Self-adjuvanted, modular, antigenic VLP for rapid response to influenza virus variability. ACS Appl. Mater. Interfaces 12, 18211\u201318224 (2020).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"737_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2018.01432","volume":"9","author":"KD Brune","year":"2018","unstructured":"Brune, K. D. & Howarth, M. New routes and opportunities for modular construction of particulate vaccines: stick, click, and glue. Front. Immunol. 9, 1\u201315 (2018).","journal-title":"Front. Immunol."},{"key":"737_CR55","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1039\/C8BM01443D","volume":"7","author":"K Ross","year":"2019","unstructured":"Ross, K. et al. Single dose combination nanovaccine provides protection against influenza A virus in young and aged mice. Biomater. Sci. 7, 809\u2013821 (2019).","journal-title":"Biomater. Sci."},{"key":"737_CR56","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1021\/nn4006544","volume":"7","author":"DP Patterson","year":"2013","unstructured":"Patterson, D. P., Rynda-Apple, A., Harmsen, A. L., Harmsen, A. G. & Douglas, T. Biomimetic antigenic nanoparticles elicit controlled protective immune response to influenza. ACS Nano 7, 3036\u20133044 (2013).","journal-title":"ACS Nano"},{"key":"737_CR57","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","volume":"10","author":"MF Bachmann","year":"2010","unstructured":"Bachmann, M. F. & Jennings, G. T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10, 787\u2013796 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"737_CR58","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1016\/j.vaccine.2009.05.029","volume":"27","author":"C Herzog","year":"2009","unstructured":"Herzog, C. et al. Eleven years of Inflexal\u00ae V\u2014a virosomal adjuvanted influenza vaccine. Vaccine 27, 4381\u20134387 (2009).","journal-title":"Vaccine"},{"key":"737_CR59","doi-asserted-by":"crossref","first-page":"10473","DOI":"10.1073\/pnas.1902805116","volume":"116","author":"S Wang","year":"2019","unstructured":"Wang, S. et al. Rational vaccinology with spherical nucleic acids. Proc. Natl Acad. Sci. 116, 10473\u201310481 (2019).","journal-title":"Proc. Natl Acad. Sci."},{"key":"737_CR60","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nri3488","volume":"13","author":"DM Smith","year":"2013","unstructured":"Smith, D. M., Simon, J. K. & Baker, J. R. Jr Applications of nanotechnology for immunology. Nat. Rev. Immunol. 13, 592\u2013605 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"737_CR61","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1021\/acsinfecdis.6b00006","volume":"2","author":"Q Wang","year":"2016","unstructured":"Wang, Q. et al. Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates. ACS Infect. Dis. 2, 361\u2013376 (2016).","journal-title":"ACS Infect. Dis."},{"key":"737_CR62","doi-asserted-by":"crossref","unstructured":"Quinlan, B. D. et al. The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement. Preprint at https:\/\/www.biorxiv.org\/content\/10.1101\/2020.04.10.036418v1 (2020).","DOI":"10.2139\/ssrn.3575134"},{"key":"737_CR63","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.xphs.2017.04.037","volume":"106","author":"WH Chen","year":"2017","unstructured":"Chen, W. H. et al. Optimization of the production process and characterization of the yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1), a SARS vaccine candidate. J. Pharm. Sci. 106, 1961\u20131970 (2017).","journal-title":"J. Pharm. Sci."},{"key":"737_CR64","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41577-020-0321-6","volume":"20","author":"A Iwasaki","year":"2020","unstructured":"Iwasaki, A. & Yang, Y. The potential danger of suboptimal antibody responses in COVID-19. Nat. Rev. Immunol. 20, 339\u2013341 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"737_CR65","doi-asserted-by":"crossref","first-page":"8218","DOI":"10.1073\/pnas.2005456117","volume":"117","author":"L Peeples","year":"2020","unstructured":"Peeples, L. News feature: Avoiding pitfalls in the pursuit of a COVID-19. Vaccin. Proc. Natl Acad. Sci. 117, 8218\u20138221 (2020).","journal-title":"Vaccin. Proc. Natl Acad. Sci."},{"key":"737_CR66","unstructured":"Zhao, J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis. (2020)."},{"key":"737_CR67","doi-asserted-by":"crossref","unstructured":"Zhang, B. et al. Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19. Preprint at https:\/\/www.medrxiv.org\/content\/10.1101\/2020.03.12.20035048v1 (2020).","DOI":"10.3389\/fmolb.2020.00157"},{"key":"737_CR68","unstructured":"LJI scientists awarded new funding to COMBAT COVID-19. La Jolla Institute for Immunology https:\/\/www.lji.org\/news-events\/news\/post\/lji-scientists-awarded-new-funding-to-combat-covid-19 (2020)."},{"key":"737_CR69","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/vaccines2030515","volume":"2","author":"W Li","year":"2014","unstructured":"Li, W., Joshi, M. D., Singhania, S., Ramsey, K. H. & Murthy, A. K. PeptidevVaccine: Progress and challenges. Vaccines 2, 515\u2013536 (2014).","journal-title":"Vaccines"},{"key":"737_CR70","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","volume":"34","author":"MO Mohsen","year":"2017","unstructured":"Mohsen, M. O., Zha, L., Cabral-Miranda, G. & Bachmann, M. F. Major findings and recent advances in virus\u2013like particle (VLP)-based vaccines. Semin. Immunol. 34, 123\u2013132 (2017).","journal-title":"Semin. Immunol."},{"key":"737_CR71","doi-asserted-by":"crossref","first-page":"e1511506","DOI":"10.1080\/2162402X.2018.1511506","volume":"7","author":"L Bezu","year":"2018","unstructured":"Bezu, L. et al. Trial watch: Peptide-based vaccines in anticancer therapy. Oncoimmunology 7, e1511506 (2018).","journal-title":"Oncoimmunology"},{"key":"737_CR72","unstructured":"ITI forms collaboration with EpiVax & PharmaJet to develop novel vaccine candidate against COVID-19 using its investigational UNITE platform. IMMUNOMIC https:\/\/www.immunomix.com\/immunomic-therapeutics-forms-collaboration-with-epivax-and-pharmajet-to-develop-novel-vaccine-candidate-against-covid-19-using-its-investigational-unite-platform (2020)."},{"key":"737_CR73","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature12978","volume":"507","author":"H Liu","year":"2014","unstructured":"Liu, H. et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 507, 519\u2013522 (2014).","journal-title":"Nature"},{"key":"737_CR74","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41565-020-0648-y","volume":"15","author":"W Wang","year":"2020","unstructured":"Wang, W. et al. Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B. Nat. Nanotechnol. 15, 406\u2013416 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"737_CR75","doi-asserted-by":"crossref","first-page":"17007","DOI":"10.1038\/celldisc.2017.7","volume":"3","author":"Z Liu","year":"2017","unstructured":"Liu, Z. et al. Coordinating antigen cytosolic delivery and danger signaling to program potent cross-priming by micelle-based nanovaccine. Cell Discov. 3, 17007 (2017).","journal-title":"Cell Discov."},{"key":"737_CR76","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/wnan.119","volume":"3","author":"EM Plummer","year":"2011","unstructured":"Plummer, E. M. & Manchester, M. Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 3, 174\u2013196 (2011).","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"737_CR77","doi-asserted-by":"crossref","first-page":"FSO401","DOI":"10.2144\/fsoa-2019-0001","volume":"5","author":"E Shoeb","year":"2019","unstructured":"Shoeb, E. & Hefferon, K. Future of cancer immunotherapy using plant virus-based nanoparticles. Future Sci. OA 5, FSO401 (2019).","journal-title":"Future Sci. OA"},{"key":"737_CR78","doi-asserted-by":"crossref","first-page":"1800139","DOI":"10.1002\/adtp.201800139","volume":"2","author":"S Shukla","year":"2019","unstructured":"Shukla, S. et al. A viral nanoparticle cancer vaccine delays tumor progression and prolongs survival in a HER2+ tumor mouse model. Adv. Ther. 2, 1800139 (2019).","journal-title":"Adv. Ther."},{"key":"737_CR79","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1021\/jacs.9b01523","volume":"141","author":"H Cai","year":"2019","unstructured":"Cai, H., Shukla, S., Wang, C., Masarapu, H. & Steinmetz, N. F. Heterologous prime-boost enhances the antitumor immune response elicited by plant-virus-based cancer vaccine. J. Am. Chem. Soc. 141, 6509\u20136518 (2019).","journal-title":"J. Am. Chem. Soc."},{"key":"737_CR80","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1021\/acs.molpharmaceut.8b00316","volume":"15","author":"AA Murray","year":"2018","unstructured":"Murray, A. A., Wang, C., Fiering, S. & Steinmetz, N. F. In situ vaccination with cowpea vs tobacco mosaic virus against melanoma. Mol. Pharm. 15, 3700\u20133716 (2018).","journal-title":"Mol. Pharm."},{"key":"737_CR81","doi-asserted-by":"crossref","first-page":"206918","DOI":"10.1155\/2012\/206918","volume":"2012","author":"M Clemente","year":"2012","unstructured":"Clemente, M. & Corigliano, M. G. Overview of plant-made vaccine antigens against malaria. J. Biomed. Biotechnol. 2012, 206918 (2012).","journal-title":"J. Biomed. Biotechnol."},{"key":"737_CR82","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1080\/19420862.2016.1227901","volume":"8","author":"S Nandi","year":"2016","unstructured":"Nandi, S. et al. Techno-economic analysis of a transient plant-based platform for monoclonal antibody production. mAbs 8, 1456\u20131466 (2016).","journal-title":"mAbs"},{"key":"737_CR83","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","volume":"514","author":"X Qiu","year":"2014","unstructured":"Qiu, X. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47\u201353 (2014).","journal-title":"Nature"},{"key":"737_CR84","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","volume":"375","author":"II PREVAIL","year":"2016","unstructured":"PREVAIL, I. I. writing group. a randomized, controlled trial of ZMapp for Ebola virus. Infect. N. Engl. J. Med. 375, 1448\u20131456 (2016).","journal-title":"Infect. N. Engl. J. Med."},{"key":"737_CR85","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/14712598.2020.1752177","volume":"20","author":"S Rosales-Mendoza","year":"2020","unstructured":"Rosales-Mendoza, S. Will plant-made biopharmaceuticals play a role in the fight against COVID-19? Expert Opin. Biol. Ther. 20, 545\u2013548 (2020).","journal-title":"Expert Opin. Biol. Ther."},{"key":"737_CR86","unstructured":"Bill Gates is able\u2014and willing\u2014to lose big money funding factories for COVID-19 vaccines. FIERCE Pharma https:\/\/www.fiercepharma.com\/vaccines\/bill-gates-plans-to-help-fund-factories-for-7-covid-19-vaccines-but-expects-only-2-will (2020)."},{"key":"737_CR87","unstructured":"BAT biotech using tobacco to make COVID-19 vaccine candidate. BioProcess International https:\/\/bioprocessintl.com\/bioprocess-insider\/therapeutic-class\/bat-biotech-using-tobacco-to-make-covid-19-vaccine-candidate (2020)."},{"key":"737_CR88","unstructured":"Researchers in Spain use biotech to produce SARS-CoV-2 vaccine in plants. International Service for the Acquisition of Agri-biotech Applications http:\/\/www.isaaa.org\/kc\/cropbiotechupdate\/article\/default.asp?ID=18065."},{"key":"737_CR89","unstructured":"Marrying molecular farming and advanced manufacturing to develop a COVID-19 vaccine. UC San Diego https:\/\/ucsdnews.ucsd.edu\/pressrelease\/marrying-molecular-farming-and-advanced-manufacturing-to-develop-a-covid-19-vaccine (2020)."},{"key":"737_CR90","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.vaccine.2016.01.001","volume":"34","author":"DD Kristensen","year":"2016","unstructured":"Kristensen, D. D., Lorenson, T., Bartholomew, K. & Villadiego, S. Can thermostable vaccines help address cold-chain challenges? Results from stakeholder interviews in six low- and middle-income countries. Vaccine 34, 899\u2013904 (2016).","journal-title":"Vaccine"},{"key":"737_CR91","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/1521-3773(20020201)41:3<459::AID-ANIE459>3.0.CO;2-O","volume":"41","author":"Q Wang","year":"2002","unstructured":"Wang, Q., Lin, T., Tang, L., Johnson, J. E. & Finn, M. G. Icosahedral virus particles as addressable nanoscale building blocks. Angew. Chem. Int. Ed. 41, 459\u2013462 (2002).","journal-title":"Angew. Chem. Int. Ed."},{"key":"737_CR92","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1039\/C7NR07182E","volume":"10","author":"A Berardi","year":"2018","unstructured":"Berardi, A., Evans, D. J., Bombelli, F. B. & Lomonossoff, G. P. Stability of plant virus-based nanocarriers in gastrointestinal fluids. Nanoscale 10, 1667\u20131679 (2018).","journal-title":"Nanoscale"},{"key":"737_CR93","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.virol.2005.08.017","volume":"343","author":"CS Rae","year":"2005","unstructured":"Rae, C. S. et al. Systemic trafficking of plant virus nanoparticles in mice via the oral route. Virology 343, 224\u2013235 (2005).","journal-title":"Virology"},{"key":"737_CR94","doi-asserted-by":"crossref","first-page":"eaau4819","DOI":"10.1126\/sciadv.aau4819","volume":"6","author":"I Bajrovic","year":"2020","unstructured":"Bajrovic, I., Schafer, S. C., Romanovicz, D. K. & Croyle, M. A. Novel technology for storage and distribution of live vaccines and other biological medicines at ambient temperature. Sci. Adv. 6, eaau4819 (2020).","journal-title":"Sci. Adv."},{"key":"737_CR95","doi-asserted-by":"crossref","first-page":"8777","DOI":"10.1021\/acsnano.7b02786","volume":"11","author":"PW Lee","year":"2017","unstructured":"Lee, P. W. et al. Biodegradable viral nanoparticle\/polymer implants prepared via melt-processing. ACS Nano 11, 8777\u20138789 (2017).","journal-title":"ACS Nano"},{"key":"737_CR96","doi-asserted-by":"crossref","first-page":"121802","DOI":"10.1016\/j.polymer.2019.121802","volume":"181","author":"DM Wirth","year":"2019","unstructured":"Wirth, D. M. & Pokorski, J. K. Design and fabrication of a low-cost pilot-scale melt-processing system. Polymer 181, 121802 (2019).","journal-title":"Polymer"},{"key":"737_CR97","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/pen.25078","volume":"59","author":"H Juster","year":"2019","unstructured":"Juster, H., Aar, Bvander & Brouwer, Hde A review on microfabrication of thermoplastic polymer-based microneedle arrays. Polym. Eng. Sci. 59, 877\u2013890 (2019).","journal-title":"Polym. Eng. Sci."},{"key":"737_CR98","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11095-013-1137-x","volume":"31","author":"B Bediz","year":"2014","unstructured":"Bediz, B. et al. Dissolvable microneedle arrays for intradermal delivery of biologics: Fabrication and application. Pharm. Res. 31, 117\u2013135 (2014).","journal-title":"Pharm. Res."},{"key":"737_CR99","first-page":"4511","volume":"12","author":"R Parhi","year":"2019","unstructured":"Parhi, R. Review of microneedle based transdermal drug delivery systems. Int. J. Pharm. Sci. Nano. 12, 4511\u201324 (2019).","journal-title":"Int. J. Pharm. Sci. Nano."},{"key":"737_CR100","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10529-019-02651-z","volume":"41","author":"M Donini","year":"2019","unstructured":"Donini, M. & Marusic, C. Current state-of-the-art in plant-based antibody production systems. Biotechnol. Lett. 41, 335\u2013346 (2019).","journal-title":"Biotechnol. Lett."},{"key":"737_CR101","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/microorganisms6020038","volume":"6","author":"AM Vieira Gomes","year":"2018","unstructured":"Vieira Gomes, A. M., Souza Carmo, T., Silva Carvalho, L., Mendon\u00e7a Bahia, F. & Parachin, N. S. Comparison of yeasts as hosts for recombinant protein production. Microorganisms 6, 38 (2018).","journal-title":"Microorganisms"},{"key":"737_CR102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-3233(03)01001-5","volume":"64","author":"A Schneemann","year":"2003","unstructured":"Schneemann, A. & Young, M. J. Viral assembly using heterologous expression systems and cell extracts. Adv. Protein Chem. 64, 1\u201336 (2003).","journal-title":"Adv. Protein Chem."},{"key":"737_CR103","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.biotechadv.2017.03.011","volume":"35","author":"JF Buyel","year":"2017","unstructured":"Buyel, J. F., Twyman, R. M. & Fischer, R. Very-large-scale production of antibodies in plants: The biologization of manufacturing. Biotechnol. Adv. 35, 458\u2013465 (2017).","journal-title":"Biotechnol. Adv."},{"key":"737_CR104","unstructured":"Craven, J. COVID-19 vaccine tracker. Regulatory Affairs Professionals Society https:\/\/www.raps.org\/news-and-articles\/news-articles\/2020\/3\/covid-19-vaccine-tracker (2020)."}],"container-title":["Nature Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41565-020-0737-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41565-020-0737-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41565-020-0737-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:00:17Z","timestamp":1684620017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41565-020-0737-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,15]]},"references-count":104,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["737"],"URL":"https:\/\/doi.org\/10.1038\/s41565-020-0737-y","relation":{},"ISSN":["1748-3387","1748-3395"],"issn-type":[{"value":"1748-3387","type":"print"},{"value":"1748-3395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,15]]},"assertion":[{"value":"25 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}